TITLE

Neoadjuvant and adjuvant therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease in the era of targeted therapy

AUTHOR(S)
Krieger, Laurence; Kristeleit, Hartmut; Chowdhury, Simon
PUB. DATE
September 2010
SOURCE
Advances in Oncology;2010, Vol. 5 Issue 3, p10
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses the relevance of neoadjuvant and adjuvant systematic therapies to renal cell carcinoma assessment. It enumerates several possible advantages of the neoadjuvant therapy including its responses in the primary tumour, the preservation of renal function in nephronsparing surgery and the availability of tissues. Results of the Phase III studies of neodajuvant setting are claimed promising while the adjuvant therapy is accordingly subject to Phase III clinical trials.
ACCESSION #
57803400

 

Related Articles

  • Targeted treatments in advanced renal cell carcinoma: focus on axitinib. Verzoni, Elena; Grassi, Paolo; Testa, Isabella; Iacovelli, Roberto; Biondani, Pamela; Garanzini, Enrico; De Braud, Filippo; Procopio, Giuseppe // Pharmacogenomics & Personalized Medicine;2014, Vol. 7, p107 

    Antiangiogenesis options have evolved rapidly in the last few years, with an increasing number of agents currently approved by the US Food and Drug Administration and European Medicines Agency. Angiogenesis inhibitors have been shown to be very effective for the treatment of metastatic renal...

  • Dynamic tumor modeling of the dose-response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial. Stein, Andrew; Wang, Wenping; Carter, Alison A.; Chiparus, Ovidiu; Hollaender, Norbert; Kim, Hyewon; Motzer, Robert J.; Sarr, Celine // BMC Cancer;2012, Vol. 12 Issue 1, p311 

    Background: The phase 3 RECORD-1 trial (NCT00410124) established the efficacy and safety of everolimus in patients with metastatic renal cell carcinoma (mRCC) who progress on sunitinib or sorafenib. In RECORD-1, patients received 10 mg everolimus daily, with dose reduction to 5 mg daily allowed...

  • Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma. Gerendash, Benjamin S.; Creel, Patricia A. // Open Access Rheumatology: Research & Reviews;Oct2017, Vol. 9, p5053 

    Cabozantinib is an oral tyrosine-kinase inhibitor whose targets include VEGFR, MET and AXL. Cabozantinib is approved for the treatment of patients with advanced clear-cell renalcell carcinoma (RCC) who have received prior antiangiogenic therapy. In the pivotal Phase III trial of second-line RCC,...

  • Genentech/Roche: another indication for the blockbuster Avastin?  // PharmaWatch: Cancer;Jan2007, Vol. 6 Issue 1, p14 

    The article focuses on the study conducted by Genentech Inc. on the performance of drug Avastin for treatment of metastatic renal cell carcinoma. The company releases its data on the drug's clinical trial showing a significant increase in progression-free survival when the drug is added to...

  • Stratifying Renal Cell Cancer Prognosis Before and After Nephrectomy. Blute, Michael L. // AUANews;Aug2007, Vol. 12 Issue 8, p1 

    The article reports on the stratification of renal cell cancer (RCC) prognosis before and after nephrectomy. According to the author, enhancing prognostic stratification after nephrectomy is important for the right surveillance and clinical trial design. The TNM staging criteria will continue to...

  • Modeling tumor growth kinetics after treatment with pazopanib or placebo in patients with renal cell carcinoma. Bonate, Peter; Suttle, A. // Cancer Chemotherapy & Pharmacology;Jul2013, Vol. 72 Issue 1, p231 

    Purpose: The purpose of this study is to characterize tumor growth kinetics in patients with renal cell carcinoma (RCC) after treatment with pazopanib or placebo and to identify predictive patient-specific covariates. Methods: Different tumor growth models that included patient-specific...

  • Pazopanib.  // Australian Prescriber;Dec2010, Vol. 33 Issue 6, p197 

    The article provides information on Pazopanib, a drug intended for metastatic renal cell carcinoma, from GlaxoSmithKline. Pazopanib is claimed to not only inhibits the formation of new blood vessels and prevents the growth of tumour, but also inhibits tyrosine kinase. Meanwhile, its approval is...

  • Novel angiogenesis agent performs well in RCC trials. Helwick, Caroline // Urology Times;3/1/2009, Vol. 37 Issue 3, p16 

    The article reports on the significant impact of pazopanib, an oral angiogenesis inhibitor, on the tumor activity of patients with metastatic renal cell carcinoma. It notes that in a randomized study of patients with stable diseases, pazopanib shows a response rate of 34% in just 68 weeks. It...

  • Role of Chemokines in Renal Cell Carcinoma. Parihar, Jaspreet S.; Tunuguntla, Hari S. G. R. // Reviews in Urology;2014, Vol. 16 Issue 3, p118 

    With new frontiers of pharmaceutical therapies focusing on tumor growth and angiogenesis, understanding the interaction between immune system and tumor microenvironment has become ever more important. Chemokines and chemokine receptors appear to play an integral role in tumor characteristics....

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics